eNLife Research raises $720K seed to detect Alzheimer's before symptoms
What's the deal? Bengaluru-based deep tech startup eNLife Research has raised US$814.8K in a seed round led by Piper SericaDealroom has a profile for this one. Try Dealroom →. The company builds AI-powered diagnostic platforms to detect Alzheimer's and other neurodegenerative diseases years before clinical symptoms appear.
What's the endgame? Founded in 2025 by Deepak Kumaran Nair, Jojo JacobDealroom has a profile for this one. Try Dealroom →, and Anish Mathew, eNLife combines biomarker detection from accessible body fluids with machine learning to spot the earliest biological signatures of disease onset. Its test can run at routine diagnostic centres and returns results within two to five hours.
Where's the money going? The proceeds will fund a blood-based biomarker platform, expand the Bengaluru R&D team, and take its first diagnostic assay from prototype to clinical-grade validation.
The startup is collaborating with researchers at IISc, NIMHANS, TIFR Hyderabad, and CBR Bengaluru to build India-specific biomarker datasets tuned to Indian genetic and lifestyle risk profiles. It expects to begin filing patents over the next nine to 18 months across biomarker binders, diagnostic assays, and its detection platform.
The signal: At $720,000, this sits in the bottom 1% of funding rounds by size — a small early bet on an ambitious clinical goal. Turning a prototype into a validated diagnostic, and defending it with patents, is the harder work that lies ahead.
Read more: Entrackr
